User login
Key clinical point: Although injectables are the most frequently used disease-modifying agents (DMAs) for multiple sclerosis (MS), the utilization of oral DMAs is increasing.
Major finding: Between 2006 and 2015, DMAs were prescribed in 45% of MS visits. Although injectables remain the most commonly prescribed DMAs (78%), the use of oral DMAs has increased (from 11% in 2010-2011 to 40% in 2014-2015) and that of injectable DMAs has decreased (from 96% in 2006-2007 to 52% in 2014-2015). Visiting a neurologist was the strongest predictor of DMA use (odds ratio, 6.61; 95% CI, 3.66-11.93).
Study details: A cross-sectional study examined the prescribing patterns and trends of DMAs in the US using the 2006-2015 National Ambulatory Medical Care Survey.
Disclosures: The study was not funded. George Hutton and Rajender Aparasu reported receiving grants from multiple pharmaceutical companies outside the submitted work. The remaining authors declared no conflicts of interest.
Citation: Earla JR et al. Res Social Adm Pharm. 2020 Mar 11. doi: 10.1016/j.sapharm.2020.02.016.
Key clinical point: Although injectables are the most frequently used disease-modifying agents (DMAs) for multiple sclerosis (MS), the utilization of oral DMAs is increasing.
Major finding: Between 2006 and 2015, DMAs were prescribed in 45% of MS visits. Although injectables remain the most commonly prescribed DMAs (78%), the use of oral DMAs has increased (from 11% in 2010-2011 to 40% in 2014-2015) and that of injectable DMAs has decreased (from 96% in 2006-2007 to 52% in 2014-2015). Visiting a neurologist was the strongest predictor of DMA use (odds ratio, 6.61; 95% CI, 3.66-11.93).
Study details: A cross-sectional study examined the prescribing patterns and trends of DMAs in the US using the 2006-2015 National Ambulatory Medical Care Survey.
Disclosures: The study was not funded. George Hutton and Rajender Aparasu reported receiving grants from multiple pharmaceutical companies outside the submitted work. The remaining authors declared no conflicts of interest.
Citation: Earla JR et al. Res Social Adm Pharm. 2020 Mar 11. doi: 10.1016/j.sapharm.2020.02.016.
Key clinical point: Although injectables are the most frequently used disease-modifying agents (DMAs) for multiple sclerosis (MS), the utilization of oral DMAs is increasing.
Major finding: Between 2006 and 2015, DMAs were prescribed in 45% of MS visits. Although injectables remain the most commonly prescribed DMAs (78%), the use of oral DMAs has increased (from 11% in 2010-2011 to 40% in 2014-2015) and that of injectable DMAs has decreased (from 96% in 2006-2007 to 52% in 2014-2015). Visiting a neurologist was the strongest predictor of DMA use (odds ratio, 6.61; 95% CI, 3.66-11.93).
Study details: A cross-sectional study examined the prescribing patterns and trends of DMAs in the US using the 2006-2015 National Ambulatory Medical Care Survey.
Disclosures: The study was not funded. George Hutton and Rajender Aparasu reported receiving grants from multiple pharmaceutical companies outside the submitted work. The remaining authors declared no conflicts of interest.
Citation: Earla JR et al. Res Social Adm Pharm. 2020 Mar 11. doi: 10.1016/j.sapharm.2020.02.016.